Plain-English translation of NCT05549297 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new immunotherapy drug called to treat advanced melanoma (skin cancer) that has spread or cannot be removed by surgery. The study compares three approaches: alone, combined with another immune medication called pembrolizumab, and standard care chosen by your doctor. Researchers want to see if this medication can help people whose melanoma has stopped responding to previous treatments.
Many people with advanced melanoma stop responding to current treatments, leaving them with limited options. This trial is exploring whether this new immune-based treatment can offer hope to patients who have already tried other therapies without success.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication alone, the new medication combined with another immune drug, or your doctor's choice of standard treatment. You will visit the clinic regularly for doses of medication (if assigned to receive it), blood tests, imaging scans to measure your tumor, and monitoring for any side effects. The trial involves multiple visits over several months, and you may need to provide additional tissue samples for research purposes to help scientists understand how the treatment works.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States